Cancer diagnostics push Abbott's 2026 EPS guidance to $5.45-$5.60

For biotech and pharma strategists, Abbott’s integration of Exact Sciences’ oncological tests marks a decisive pivot from pandemic-era diagnostics to durable, high-value cancer screening. Cologuard and Oncotype DX are not only replacing evaporating COVID-19 revenues but also positioning Abbott in the lucrative precision oncology market, with potential for margin expansion as screening adherence rebounds.

Abbott Laboratories delivered a strong second-quarter 2026 earnings beat and raised its full-year profit forecast, underscoring the resilience of its medical device and diagnostics portfolio in a challenging healthcare environment. The company reported adjusted earnings per share of $1.31, surpassing the consensus estimate of $1.28, while total revenue reached $12.59 billion, exceeding expectations of $12.5 billion. The primary growth engines were the medical device segment, up 9% to $5.85 billion, and the diabetes care unit, which climbed 11% to $2.19 billion on the back of continuous glucose monitor adoption. These results prompted management to lift the 2026 adjusted EPS guidance to a range of $5.45 to $5.60, up from $5.38–$5.58, signaling sustained operational momentum.

“

The company reported adjusted earnings per share of $1.31, surpassing the consensus estimate of $1.28, while total revenue reached $12.59 billion, exceeding expectations of $12.5 billion.

The quarter’s standout narrative is the successful integration of Exact Sciences’ cancer diagnostics assets, acquired to offset the secular decline in COVID-19 testing revenue. Cologuard, a non-invasive colorectal cancer screening test, and Oncotype DX, a breast cancer assay, are now positioned as high-growth, recurring-revenue streams. This strategic pivot not only diversifies Abbott’s diagnostic mix but also aligns with broader industry trends favoring precision oncology and decentralized testing. While COVID-19 product sales continue to wane — an industry-wide headwind — the new cancer testing portfolio provided a critical earnings buffer and is expected to become a material contributor as payer coverage expands and screening rates recover post-pandemic.

The medical device performance defied broader concerns about weaker surgical volumes and rising uninsured patient levels. Management highlighted that electrophysiology and structural heart procedures — areas where Abbott holds strong market positions — remained relatively insulated. This suggests that Abbott’s product mix, which leans toward advanced, minimally invasive cardiac care like MitraClip and EnSite mapping systems, is less sensitive to elective surgery softness. The 9% growth in devices, which topped the $5.82 billion Street forecast, indicates that hospitals are prioritizing capital purchases for high-acuity, high-reimbursement procedures even while other elective volumes may be softening.

Diabetes care was another bright spot, driven by the FreeStyle Libre franchise and the newer Lingo over-the-counter CGM. An 11% sales increase reflects not only new patient starts but also deepening adoption among Type 2 diabetics and health-conscious consumers. The competitive landscape in CGM is intensifying, with Dexcom and Medtronic advancing their sensors, but Abbott’s scale and manufacturing efficiency keep it ahead. The Libre 3 platform, offering smaller form factors and cloud connectivity, is likely a growth accelerator, particularly as reimbursement expands internationally.